HemostOD raises CHF 4.3 million in seed-extension to scale donor-free…

Team S · 2025-10-11T06:54:01.000Z

HemostOD, an EPFL spin-off based in Lausanne that develops donor-free human blood platelets using immortalized hematopoietic stem cells and a proprietary bioreactor platform, closed a CHF 4.3 million seed-extension round. The round was co-led by Polytech Ventures and Orenok Holdings, with participation from the Lichtsteiner Foundation and private investors. The funding will be used to launch a commercial-scale pilot production line and prepare for a pre-IND meeting with the U.S. Food and Drug Administration; the company has now raised CHF 6.0 million in total since its initial seed round. Founders/key people: Faouzi Khechana (CEO) is quoted in the coverage.

Member Login Get Access

HemostOD raises CHF 4.3 million in seed-extension to scale donor-free… | Newnex